7.6 C
Alba Iulia
Saturday, January 23, 2021

Pfizer files with FDA for emergency use of its COVID-19 vaccine in US

Must Read

Bitcoin tumbles down 10 percent on fears of US crackdown

The price of bitcoin plunged more than 10 percent amid fears of a US regulatory crackdown on...

Wall Street rallies on inauguration day, Biden breaks Hoover’s record for stock gains

US stocks closed at record highs Wednesday as President Joe Biden was sworn in as the 46th president...

Rapper Jay-Z launches $10 million fund for minority-owned pot companies

Music mogul, Jay-Z has started an investment fund to help minority marijuana entrepreneurs break into the booming...

Pfizer Inc. and its German partner, BioNTech SE will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable the use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020.

The action comes days after Pfizer Inc. announced appears 95% effective at preventing mild to severe COVID-19 disease in a large, ongoing study.

The companies said that protection plus a good safety record means the vaccine should qualify for emergency use authorization, something the Food and Drug Administration can grant before the final testing is fully complete. In addition to Friday’s FDA submission, they have already started “rolling” applications in Europe and the U.K. and intend to submit similar information soon.

“Our work to deliver a safe and effective vaccine has never been more urgent, as we continue to see an alarming rise in the number of cases of COVID-19 globally. Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential,” said Dr. Albert Bourla, Pfizer Chairman and CEO in a statement to the press. “We look forward to the upcoming Vaccines and Related Biological Products Advisory Committee discussion and continue to work closely with the FDA and regulatory authorities worldwide to secure authorization of our vaccine candidate as quickly as possible.”

According to today’s statement, while Pfizer and BioNTech await potential authorization or approval from regulatory agencies, the companies continue to work in collaboration with governments and Ministries of Health around the world that will distribute the vaccine, subject to authorization or approval, to help ensure it can reach those most in need as quickly as possible.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest News

Bitcoin tumbles down 10 percent on fears of US crackdown

The price of bitcoin plunged more than 10 percent amid fears of a US regulatory crackdown on...

Wall Street rallies on inauguration day, Biden breaks Hoover’s record for stock gains

US stocks closed at record highs Wednesday as President Joe Biden was sworn in as the 46th president — with the new commander-in-chief...

Rapper Jay-Z launches $10 million fund for minority-owned pot companies

Music mogul, Jay-Z has started an investment fund to help minority marijuana entrepreneurs break into the booming cannabis business.

Chipotle And The Shawn Mendes Foundation team up to launch sustainability grants

Chipotle Mexican Grill has partnered with Shawn Mendes and the Shawn Mendes Foundation to launch "Wonder Grants" supporting young innovators in sustainability, as well...

Jobless Numbers: 965,000 new claims as COVID-19 pressures labor market

The federal jobless claims numbers are out and it shows 965,000 new applications were filed for unemployment benefits last week — an...
- Advertisement -

More Articles Like This

- Advertisement -